Clinical trial · Observational
Uterine Leiomyoma Treatment With Radiofrequency Ablation (ULTRA) Registry
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The ULTRA Registry is a nationwide observational arm of the ULTRA trial. Data from the ULTRA Registry will be used to evaluate the long-term safety and efficacy of laparoscopic RF ablation (Acessa). The ULTRA Registry will recruit women age 21 or older who plan to undergo or have undergone laparoscopic RF ablation (Acessa) or myomectomy within the United States. Participants will be recruited through study materials distributed at clinical offices across the country where gynecologists are performing laparoscopic RF ablation (Acessa). Study participants will consent to participate in a 3 year prospective study conducted by UCSF but the fibroid procedure will be performed by the study participants' own gynecologist. We will evaluate changes in fibroid-related symptoms from pre-treatment values to 6, 12, 18, 24, 30, and 36 months after RFA (Acessa). We will determine long-term efficacy of RFA (Acessa) by evaluating the rate of re-treatment for symptomatic fibroids after the RFA (Acessa) procedure versus myomectomy. Participants will be asked for permission to review their medical records to assess surgical and pregnancy outcomes. UC San Francisco will have oversight of all scientific and administrative aspects of the study. All study data will be stored securely in a HIPAA compliant, secure database monitored by the UC San Francisco Coordinating Center.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Uterine Fibroids | Uterine Corpus Leiomyoma | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Myomectomy of fibroids | Procedure | — | UNRESOLVED |
| Radiofrequency ablation of fibroids | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Women undergoing radiofrequency ablation.
- description
- Most women (75%) in the trial will be in the group who receive treatment with radiofrequency ablation (Acessa).
- interventionNames
- Procedure: Radiofrequency ablation of fibroids
- label
- Women undergoing myomectomy
- description
- About 25% of women in the trial will be in the group who receive treatment with myomectomy.
- interventionNames
- Procedure: Myomectomy of fibroids
Primary outcomes (1)
- measure
- Changes in fibroid-related symptoms after the RFA or myomectomy procedure.
- timeFrame
- Baseline to 3 years
- description
- We will use standard questionnaires for women with fibroids to assess changes in fibroid symptoms including menstrual pattern and flow and overall quality of life.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 21 Years
Show eligibility criteria text
Inclusion Criteria: * Planning to undergo or have undergone\* RF ablation (Acessa) or myomectomy (laparoscopic or abdominal) for treatment of uterine fibroids. * Able to give informed consent * Speak English or Spanish * Women enrolled at contracted clinical sites must enroll prior to their RF ablation treatment Exclusion Criteria: * \<21 years of age * Plan to undergo hysteroscopic myomectomy
References
Publications (1)
- DERIVEDRubio EM, Hilton JF, Bent S, Parvataneni R, Oberman E, Saberi NS, Varon S, Schembri M, Waetjen LE, Jacoby VL. Complementary and Alternative Medicine Use Among Women with Symptomatic Uterine Fibroids. J Womens Health (Larchmt). 2023 May;32(5):546-552. doi: 10.1089/jwh.2022.0094. Epub 2023 Apr 6. PMID 37023398